Estrella Immunopharma, INC. (ESLAW) — 8-K Filings

8-K Filings (24)

• Estrella Immunopharma Files 8-K — Dec 4, 2025 Risk: low
  On December 4, 2025, Estrella Immunopharma, Inc. filed an 8-K report. The filing indicates the company's fiscal year ends on December 31st and provides its busi
• 8-K Filing — Nov 6, 2025
• Estrella Immunopharma Files 8-K for Other Events — Sep 29, 2025 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on September 29, 2025, reporting an event that occurred on September 23, 2025. The filing is related to "Other Events"
• Estrella Immunopharma Reports Director/Officer Changes — Sep 26, 2025 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on September 26, 2025, reporting events as of September 22, 2025. The filing indicates a departure of directors or cert
• Estrella Immunopharma Faces Delisting Concerns — Aug 7, 2025 Risk: high
  Estrella Immunopharma, Inc. filed an 8-K on August 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the
• Estrella Immunopharma Files 8-K — Jun 5, 2025 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on June 5, 2025, reporting other events and financial statements. The company, formerly known as TradeUP Acquisition Co
• Estrella Immunopharma Files 8-K on Key Agreements — Jun 3, 2025 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on June 3, 2025, reporting on events as of May 30, 2025. The filing indicates an entry into a material definitive agree
• Estrella Immunopharma Files 8-K — May 29, 2025 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on May 29, 2025, reporting other events and financial statements. The company, formerly known as TradeUP Acquisition Co
• Estrella Immunopharma Faces Delisting Concerns — May 2, 2025 Risk: high
  Estrella Immunopharma, Inc. filed an 8-K on May 2, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of April
• Estrella Immunopharma Files 8-K — Feb 21, 2025 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on February 21, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as
• Estrella Immunopharma Files 8-K — Feb 20, 2025 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on February 20, 2025, reporting an event on February 19, 2025. The filing indicates a change in the company's structure
• Estrella Immunopharma Files 8-K: Other Event Reported — Dec 16, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on December 16, 2024, reporting an "Other Event." The filing does not contain specific details about the event, dollar
• Estrella Immunopharma Files 8-K on Material Agreement — Dec 6, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on December 6, 2024, reporting a material definitive agreement entered into on December 4, 2024. The filing also includ
• Estrella Immunopharma Changes Fiscal Year End — Nov 26, 2024 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on November 26, 2024, reporting a change in its fiscal year end to December 31st. The company, formerly known as TradeU
• Estrella Immunopharma Faces Delisting Notice — Nov 25, 2024 Risk: high
  Estrella Immunopharma, Inc. filed an 8-K on November 25, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, form
• Estrella Immunopharma Appoints New CMO & CSO, CMO Departs — Aug 20, 2024 Risk: medium
  Estrella Immunopharma, Inc. announced on August 14, 2024, the appointment of Dr. Jianjun Liu as Chief Medical Officer and Dr. Hongbo Li as Chief Scientific Offi
• Estrella Immunopharma Files 8-K with Financials — Aug 6, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on August 6, 2024, reporting events as of July 31, 2024. The filing includes financial statements and exhibits, and det
• Estrella Immunopharma Files 8-K with Financials — Jul 2, 2024 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on July 2, 2024, reporting events that occurred on June 26, 2024. The filing includes financial statements and exhibits
• Estrella Immunopharma Files 8-K for Material Agreement — May 13, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on May 13, 2024, reporting the entry into a material definitive agreement and filing financial statements and exhibits.
• Estrella Immunopharma Files 8-K — Apr 10, 2024 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on April 10, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kn
• Estrella Immunopharma Files 8-K — Mar 11, 2024 Risk: low
  Estrella Immunopharma, Inc. filed an 8-K on March 8, 2024, reporting other events and financial statements. The company, formerly known as TradeUP Acquisition C
• Estrella Immunopharma Files 8-K for Material Agreement — Mar 7, 2024 Risk: medium
  Estrella Immunopharma, Inc. filed an 8-K on March 7, 2024, reporting a material definitive agreement and financial statements. The company, formerly known as Tr
• Estrella Immunopharma Changes Certifying Accountant — Feb 2, 2024
  Estrella Immunopharma, Inc. (ESLA) announced on January 30, 2024, that it is changing its independent accounting firm. This is a standard procedural update, ind
• Estrella Immunopharma Files Routine 8-K on Jan 30 — Jan 30, 2024
  Estrella Immunopharma, Inc. filed an 8-K on January 30, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing, under SEC File Numb

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX